Gilead strikes $4.9bn deal to buy Forty Seven
The acquisition is set to strengthen Gilead’s immuno-oncology research and development portfolio with drugs such as Forty Seven’s magrolimab.
Read More
Tag: magrolimab
- Kainova reports positive results for DT‑9081 in advanced solid tumours
- EnteroBiotix completes enrolment for trial of EBX‑102‑02
- Lundbeck completes patient randomisation early in global MSA trial
- Incyte treatment for advanced anal cancer approved in Europe
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
